Greenwich LifeSciences, Inc. — FY2022 Form 10-K
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2022; it does not provide standalone fourth-quarter results. Greenwich is a clinical-stage biopharmaceutical company developing GLSI-100 (GP2 plus GM-CSF), an investigational immunotherapy intended to prevent breast cancer recurrence. The company had no approved products or revenue.
Key financial metrics
| Metric | FY2022 / year-end | FY2021 / prior year-end |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $6.48 million | $3.56 million |
| General and administrative expense | $1.56 million | $1.04 million |
| Total operating expenses | $8.04 million | $4.60 million |
| Net loss | $7.83 million; $0.61 per share | $4.57 million; $0.35 per share |
| Cash | $13.47 million | $27.20 million |
| Net cash used in operations | $6.20 million | $4.29 million |
| Total liabilities | $0.26 million | $0.39 million |
| Accumulated deficit | $41.47 million | $33.65 million |
There was no revenue, so revenue growth and operating margins are not meaningful. The filing reports no material debt balance; year-end liabilities comprised $220,845 in accounts payable and accrued interest and $42,060 in unreimbursed expenses. Cash-flow details show no investing cash flows in either year. FY2022 financing cash use of $7.54 million was for share repurchases; FY2021 financing cash provided was $2.84 million, net of related-party loan repayments and including offering and warrant proceeds.
Changes versus prior year
- Net loss increased by $3.25 million, primarily reflecting increased Phase III manufacturing and clinical expenses and higher cash and stock-based compensation.
- R&D expense rose 82% to $6.48 million; G&A expense rose 51% to $1.56 million.
- Cash decreased by $13.74 million. In addition to operating cash use, the company spent $7.54 million repurchasing and canceling approximately 519,828 shares.
- Year-end stockholders’ equity declined to $13.21 million from $26.83 million.
Outlook, commentary, risks, and unusual items
- Clinical program: The company reported that the Phase III Flamingo-01 trial had commenced and was enrolling in the U.S. The trial evaluates GLSI-100 against placebo in selected HER2-positive, HLA-A*02-positive patients following trastuzumab-based treatment. An FDA clinical hold was removed on July 11, 2022 after the company addressed manufacturing-related issues.
- Earlier clinical data: In the Phase IIb trial, the company reported no recurrences in the HER2/neu 3+ efficacy population treated with GLSI-100 versus an 11% recurrence rate in the placebo arm after median five-year follow-up (p=0.0338). The reported efficacy population required patients to be treated, followed, and remain disease-free during the first six months; these findings do not establish Phase III efficacy. The filing reports no serious adverse events considered related to GLSI-100 among 146 treated patients across four trials.
- Funding and runway: Management stated that cash at December 31, 2022 was expected to fund operating expenses and capital requirements for at least 12 months from the March 31, 2023 filing date, but would not fund completion of development and regulatory approval. The company has no committed source of additional capital and may need financing or strategic transactions. It estimated that completing an interim analysis and filing a U.S. BLA could cost more than $30 million.
- Principal risks: Trial enrollment, execution and outcomes; regulatory approval; further capital needs and dilution; reliance on third-party manufacturers, CROs and suppliers; and competition. GM-CSF is available from a single manufacturer, and the company reported no supply agreement for it. GP2 is licensed from HJF, with potential milestone payments of up to $5.7 million and sales royalties of 2.5%–5% under the license terms.
- Controls and audit: Management concluded that disclosure controls and internal control over financial reporting were ineffective at year-end 2022 because of material weaknesses involving segregation of duties and insufficient written accounting, IT, reporting and record-keeping procedures. The independent auditor issued an unqualified opinion on the financial statements but was not engaged to opine on internal control effectiveness.
- Other items: The company authorized a share repurchase program of up to $10 million through March 31, 2023; approximately $7.54 million had been used by year-end. No material legal proceedings or off-balance-sheet arrangements were reported. No specific revenue or earnings guidance was provided.
Important facts for investors to verify
- Current cash, actual cash burn, and financing needs relative to management’s stated minimum 12-month runway.
- Flamingo-01 enrollment, trial milestones and interim-analysis timing, including whether recruitment or manufacturing issues have changed the schedule or cost.
- Whether the conditional Phase IIb efficacy finding is replicated in the randomized Phase III population and whether safety remains acceptable.
- Availability and continuity of GM-CSF and other third-party manufacturing and clinical-trial supplies.
- Progress in remediating the disclosed material weaknesses in internal control over financial reporting.